OKYO Pharma Secures Additional $2.05M from Over-Allotment, Bringing Total Offering Proceeds to $22M

summarizeSummary

OKYO Pharma announced the partial exercise of an over-allotment option, raising an additional $2.05 million and bringing the total gross proceeds from its recent public offering to approximately $22 million.

check_boxKey Events

• Underwriter Exercises Over-Allotment Option

  The underwriter purchased an additional 1,109,060 ordinary shares on March 12, 2026, as part of a previously announced public offering.

• Total Offering Proceeds Reach $22 Million

  This exercise brings the total gross proceeds to the company from the public offering to approximately $22 million, before deducting underwriting discounts and commissions.

• Offering Priced at a Premium

  The shares were sold at a public offering price of $1.85 per share, which is above the current market price of $1.70.

• Addresses Going Concern Warning

  This substantial capital raise provides critical funding, extending the company's financial runway following a previous "going concern" disclosure in its F-3 registration statement.

auto_awesomeAnalysis

This filing confirms the successful completion of a significant capital raise for OKYO Pharma. The exercise of the over-allotment option indicates strong demand for the initial offering. The total proceeds of approximately $22 million represent a substantial infusion of capital, which is critical for the company, especially given its prior "going concern" warning. The offering was priced at $1.85 per share, a premium to the current stock price of $1.70, suggesting institutional confidence at the time of the transaction. While the offering is dilutive, securing this level of funding significantly extends the company's financial runway and mitigates immediate liquidity concerns.